Discuss Nektar Therapeutics
Nektar Therapeutics
WKN: 165417 / Symbol: NKTR / Name: Nektar / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
0,58 €
2,03 %
Sell Nektar Therapeutics
Buy Nektar Therapeutics
Nektar Therapeutics (NASDAQ: NKTR) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $3.00 to $2.00. They now have a "sell" rating on the stock.
Ratings data for NKTR provided by MarketBeat
Nektar Therapeutics (NASDAQ: NKTR) was upgraded by analysts at TD Cowen from a "market perform" rating to an "outperform" rating.
Ratings data for NKTR provided by MarketBeat
Nektar Therapeutics (NASDAQ: NKTR) had its "underweight" rating re-affirmed by analysts at JPMorgan Chase & Co..
Ratings data for NKTR provided by MarketBeat
Nektar Therapeutics (NASDAQ: NKTR) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $2.00 price target on the stock.
Ratings data for NKTR provided by MarketBeat
Nektar Therapeutics (NASDAQ: NKTR) had its "buy" rating re-affirmed by analysts at BTIG Research. They now have a $4.00 price target on the stock.
Ratings data for NKTR provided by MarketBeat
Nektar Therapeutics (NASDAQ: NKTR) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $7.00 price target on the stock.
Ratings data for NKTR provided by MarketBeat
Nektar Therapeutics (NASDAQ: NKTR) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $6.50 price target on the stock.
Ratings data for NKTR provided by MarketBeat
Nektar Therapeutics (NASDAQ: NKTR) is now covered by analysts at B. Riley. They set a "buy" rating and a $4.00 price target on the stock.
Ratings data for NKTR provided by MarketBeat
Nektar Therapeutics (NASDAQ: NKTR) was upgraded by analysts at B. Riley to a "strong-buy" rating.
Ratings data for NKTR provided by MarketBeat
Nektar Therapeutics (NASDAQ: NKTR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.50 price target on the stock.
Ratings data for NKTR provided by MarketBeat
Nektar Therapeutics (NASDAQ: NKTR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.50 price target on the stock.
Ratings data for NKTR provided by MarketBeat
Nektar Therapeutics (NASDAQ: NKTR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.50 price target on the stock.
Ratings data for NKTR provided by MarketBeat
Nektar Therapeutics (NASDAQ: NKTR) was upgraded by analysts at Oppenheimer Holdings Inc. from a "market perform" rating to an "outperform" rating. They now have a $6.00 price target on the stock.
Ratings data for NKTR provided by MarketBeat
Nektar Therapeutics (NASDAQ: NKTR) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $2.00 price target on the stock, up previously from $1.00.
Ratings data for NKTR provided by MarketBeat
Nektar Therapeutics (NASDAQ: NKTR) had its price target raised by analysts at HC Wainwright from $6.50 to $120.00. They now have a "buy" rating on the stock.
Ratings data for NKTR provided by MarketBeat
Nektar Therapeutics (NASDAQ: NKTR) had its price target raised by analysts at BTIG Research from $60.00 to $100.00. They now have a "buy" rating on the stock.
Ratings data for NKTR provided by MarketBeat
Nektar Therapeutics (NASDAQ: NKTR) had its price target raised by analysts at B. Riley from $60.00 to $85.00. They now have a "buy" rating on the stock.
Ratings data for NKTR provided by MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $100.00 price target on the stock.
Ratings data for NKTR provided by MarketBeat
Neueste Beiträge
Deutsche_Bank_Aktien in BASF SE ADR diskutieren